Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2012.48.5805PMID 24190112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

  2012cited by this paper
• Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

  2011cited by this paper
• A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

  2011cited by this paper
• Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

  2011cited by this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cited by this paper
• Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

  2010cited by this paper
• Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

  2010cited by this paper
• Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.

  2010cited by this paper
• Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

  2009cited by this paper
• Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

  2009cited by this paper
• A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

  2009cited by this paper
• Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.

  2009cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008cited by this paper
• Capecitabine and oxaliplatin for advanced esophagogastric cancer.

  2008cited by this paper
• A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).

  2007cited by this paper
• Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

  2006cited by this paper
• Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer: A Phase II Study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106)

  2005cited by this paper
• Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer

  2002cited by this paper
• Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A)].

  1998cited by this paper
• Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

  1995cited by this paper
• Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

  1994cited by this paper
• Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

  1993cited by this paper

• Time toxicity associated with treatment of metastatic or unresectable gastro-oesophageal cancers in the second-line setting

  2026cites this paper
• Japanese gastric cancer treatment guidelines 2025 (7th edition)

  2026cites this paper
• Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial.

  2026cites this paper
• Relative Clinical Efficacy and Safety of Second- or Later-Line Treatments for Advanced and Metastatic Gastric Cancer: A Rapid Review and Network Meta-Analysis

  2026cites this paper
• Outcomes of Ramucirumab Monotherapy for Advanced Gastric Cancer in a Multi-institutional Cohort Study in Japan

  2026cites this paper
• Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• A machine-learning powered liquid biopsy predicts response to paclitaxel plus ramucirumab in advanced gastric cancer: results from the prospective IVY trial

  2025cites this paper
• Comparison of the prognostic effect of taxane regimens combined with ramucirumab before nivolumab for advanced gastric cancer

  2025cites this paper
• Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

  2025cites this paper
• Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma

  2025cites this paper
• PSMA-targeted Small Molecule-Drug Conjugates based on a Post-Prolyl Peptidase Cleavable Linker for the Treatment of Prostate Cancer.

  2025cites this paper
• Efficacy and safety of antibody-drug conjugates for HER2-expressing advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis

  2025cites this paper
• Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer

  2025cites this paper
• Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.

  2025cites this paper
• DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

  2025cites this paper
• Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial

  2025cites this paper
• The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions

  2025influential citation
• Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

  2025cites this paper
• Phase I study of intraperitoneal irinotecan with systemic capecitabine and oxaliplatin for patients with gastric peritoneal metastases.

  2025cites this paper
• Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer

  2025cites this paper
• Mismatch between evidence and related clinical recommendations about the treatment of advanced esophageal cancer patients with anticancer drugs: A critical historical review.

  2025cites this paper
• Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial

  2025cites this paper
• German guidelines for the diagnosis and treatment of squamous-cell carcinoma and adenocarcinoma of the esophagus—version 4.0

  2025cites this paper
• Pharmacotherapy for previously treated gastric cancer patients: current options and future developments

  2025cites this paper
• Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58–UCGI35–REGIRI Unicancer randomised phase II study

  2025cites this paper
• Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab

  2025cites this paper
• Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial

  2025cites this paper
• Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)

  2025cites this paper
• Recent advances in palliative systemic therapy for locally advanced unresectable or metastatic gastric cancer: a narrative review

  2025cites this paper
• Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023

  2025cites this paper
• Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer

  2025cites this paper
• The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer

  2024cites this paper
• Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

  2024cites this paper
• HER2-low gastric cancer: is the subgroup targetable?

  2024cites this paper
• Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention.

  2024cites this paper
• Network Meta-analysis of Randomized Controlled Trials in Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: Comparisons Involving Ramucirumab

  2024cites this paper
• Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials

  2024cites this paper
• Gastric transcatheter chemoembolization combined with systemic chemotherapy vs. systemic chemotherapy alone for patients with advanced gastric cardiac cancer presenting with dysphagia: A case control study

  2024cites this paper
• Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer

  2024cites this paper
• Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

  2024cites this paper
• Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer

  2024cites this paper
• Strategic approaches in oral squamous cell carcinoma diagnostics using liquid biopsy

  2024cites this paper
• Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study

  2024influential citation
• Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study

  2024cites this paper
• Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.

  2024cites this paper
• Chronological improvement of survival in patients with advanced gastric cancer over 15 years

  2024cites this paper
• Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

  2024cites this paper
• Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE

  2024cites this paper
• Efficacy of ramucirumab and subsequent nivolumab therapy in patients with advanced gastric cancer: A retrospective study

  2024cites this paper
• Impact of the number of therapy lines on survival in advanced gastric and esophagogastric adenocarcinoma - a real-world retrospective analysis from Croatia.

  2024cites this paper
• A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer

  2024cites this paper
• S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

  2024cites this paper
• Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis

  2024cites this paper
• Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial

  2024cites this paper
• Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer

  2024cites this paper
• Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer

  2024cites this paper
• Advances in diagnosis and management of cancer of the esophagus

  2024cites this paper
• In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.

  2024cites this paper
• Current status and perspectives of esophageal cancer: a comprehensive review

  2024cites this paper
• Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy

  2024cites this paper
• Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors

  2024cites this paper
• FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  2024cites this paper
• Impact of gastrectomy on efficacy and safety of second‐line chemotherapy patients with advanced gastric cancer: Exploratory analysis of two randomized phase III trials

  2024cites this paper
• Post-marketing surveillance of anticancer drugs using natural language processing of electronic medical records

  2024cites this paper
• Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer

  2024cites this paper
• PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study

  2024influential citation
• Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis

  2023cites this paper
• Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer

  2023cites this paper
• S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

  2023cites this paper
• Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer

  2023cites this paper
• Mechanisms of esophageal cancer metastasis and treatment progress

  2023cites this paper
• The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review

  2023cites this paper
• Medikamentöse Therapie des fortgeschrittenen/metastasierten Magenkarzinoms

  2023cites this paper
• S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus

  2023cites this paper
• Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update

  2023cites this paper
• A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

  2023cites this paper
• Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials

  2023cites this paper
• INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

  2023cites this paper
• High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study

  2023cites this paper
• Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial

  2023cites this paper
• Clinical Management of Gastric Cancer Treatment Regimens.

  2023cites this paper
• Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data

  2023cites this paper
• Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression

  2023cites this paper
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

  2023cites this paper
• Correlation of multiple endpoints in the first‐line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials

  2023cites this paper
• Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

  2023cites this paper
• State of the scientific evidence and recommendations for the management of older patients with gastric cancer.

  2023cites this paper
• Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study

  2023cites this paper
• German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer

  2023cites this paper
• Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer

  2023cites this paper
• Second-Line Chemotherapy in Gastric Cancer: a Retrospective Study

  2023cites this paper
• Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

  2023cites this paper
• Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach

  2023cites this paper
• Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort

  2023cites this paper
• Nomogram based on clinical characteristics for predicting overall survival in gastric cancer patients with preoperative anemia

  2023cites this paper
• The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer.

  2023cites this paper
• Pattern and time point of relapse in locally advanced esophagogastric adenocarcinoma after multimodal treatment: implications for a useful structured follow-up

  2023cites this paper
• HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

  2023cites this paper
• Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway

  2023cites this paper